{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-050163","form_type":"8-K","ticker":"BLFS","cik":"0000834365","company_name":"BIOLIFE SOLUTIONS INC","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.302199+00:00","generated_at":"2026-05-17T00:06:26.269880+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioLife Q3 total rev $28.1M (+31% YoY); net income $0.6M; raises cell processing guidance to $93-94M","bullets":["Total Q3 revenue $28.1M (up 31% YoY); Cell Processing revenue $25.4M (up 33% YoY).","GAAP net income $0.6M vs loss $0.5M in Q3 2024; adjusted EBITDA $7.8M (28% of revenue).","Full-year Cell Processing revenue guidance raised to $93-94M (from $91-93M); total rev $95-96M excl. evo.","Completed sale of evo cold chain logistics on Oct 6 for $25.5M cash, streamlining to pure-play cell processing.","Cash and marketable securities $98.4M as of Sep 30; no evo proceeds included."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-050163","json":"https://secwatch.observer/filing/0001628280-25-050163.json","markdown":"https://secwatch.observer/filing/0001628280-25-050163.md","text":"https://secwatch.observer/filing/0001628280-25-050163.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/834365/000162828025050163/0001628280-25-050163-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/834365/000162828025050163/blfs-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:06:26.269880+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}